ETFDH: A Potential Drug Target Or Biomarker (G2110)

Target Name: ETFDH

NCBI ID: G2110

ETFDH

ETFDH: A Potential Drug Target Or Biomarker

Electron transfer flavoprotein ubiquinone oxidoreductase (ETFFDH) is a protein that plays a crucial role in the electron transport chain of the mitochondria. It is a key enzyme in the electron transport chain, which is responsible for transporting electrons from the mitochondria's matrix to its inner membrane. ETFDH is a ubiquinone oxidoreductase, which means it is involved in the oxidation of ubiquinone, a molecule that is found in the mitochondria's matrix. This article will discuss the potential implications of ETFDH as a drug target or biomarker.

ETFDH is a 23-kDa protein that is located in the mitochondria's matrix. It is a member of the BH domain family, which is a family of proteins that are involved in the transfer of electrons in a variety of organisms, including humans. ETFDH is a key enzyme in the electron transport chain, as it is responsible for the transfer of electrons from the mitochondria's matrix to its inner membrane. This process is called ubiquinone oxidoreductase, and it is a crucial step in the electron transport chain.

The electron transport chain is a complex series of proteins that are responsible for transporting electrons from the mitochondria's matrix to its inner membrane. It is made up of four different proteins, which are ETFDH, Fe-S-Cu-NADH dehydrogenase, Fe-S-Cu-NAD+ redoxase, and Co-Q. These proteins work together to ensure that electrons are efficiently transported from the mitochondria's matrix to its inner membrane. ETFDH is a key enzyme in this process, as it is responsible for the transfer of electrons from the mitochondria's matrix to its inner membrane.

ETFDH is a ubiquinone oxidoreductase, which means it is involved in the oxidation of ubiquinone, a molecule that is found in the mitochondria's matrix. This process is called ubiquinone oxidoreductase, and it is a crucial step in the electron transport chain. In the electron transport chain, ubiquinone is first converted to ubiquinone-2, which is then oxidized to ubiquinone-3 by ETFDH. This conversion is critical for the electron transport chain to function properly.

ETFDH is also involved in the regulation of the electron transport chain. It is known to play a role in the regulation of the electron transport chain's efficiency, as well as the stability of the electron transport chain. This is important for the proper functioning of the electron transport chain, as it ensures that electrons are efficiently transported from the mitochondria's matrix to its inner membrane.

In addition to its role in the electron transport chain, ETFDH is also involved in the regulation of cellular processes. For example, it is known to play a role in the regulation of mitochondrial fusion, which is the process by which new mitochondria are formed in the cell. This is important for the cell's energy production, as it is the energy-producing process of the cell.

As a result of its involvement in the electron transport chain and its regulation of cellular processes, ETFDH is a potential drug target or biomarker. IfETFDH were to be targeted by a drug, it could be used to treat a variety of conditions, including neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, ETFDH is also a potential biomarker for a variety of diseases, including cancer, as it is involved in the regulation of the electron transport chain.

In conclusion, ETFDH is a protein that plays a crucial role in the electron transport chain of the mitochondria. It is a key enzyme in the electron transport chain, as it is responsible for

Protein Name: Electron Transfer Flavoprotein Dehydrogenase

Functions: Accepts electrons from ETF and reduces ubiquinone

The "ETFDH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETFDH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets